Point72 Asset Management
AKBA icon

Point72 Asset Management’s Akebia Therapeutics AKBA Stock Holding History

Point72 Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-475,500
Closed -$341K – 1383
2022
Q1 		$341K Buy
+475,500
New +$1.02M ﹤0.01% 1039

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Point72 Asset Management's AKBA Position: Q3 2025 in Review

Point72 Asset Management sold out of Akebia Therapeutics (AKBA) in Q3 2025, closing a stake of 93,721 shares — an estimated $341K sold.

Point72 Asset Management first reported a position in AKBA in Q4 2015 and held it in 12 quarters. The position peaked at $15M in Q1 2020. 177 funds tracked by Wall St. Rank hold AKBA as of Q3 2025.

  • Point72 Asset Management reported no remaining Akebia Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Point72 Asset Management sold 93,721 Akebia Therapeutics shares in Q3 2025, an estimated $341K.
  • Point72 Asset Management first reported a position in Akebia Therapeutics in Q4 2015 and held it in 12 quarters.
  • Point72 Asset Management's Akebia Therapeutics position peaked at $15M in Q1 2020.
  • 177 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2025.

Based on Point72 Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.